Candida

Chapter 226 Candida




Candidiasis encompasses many clinical syndromes that may be caused by several species of Candida. Invasive candidiasis (Candida infections of the blood and other sterile body fluids) is a leading cause of infection-related mortality in hospitalized immunocompromised patients.


Candida exists in 3 morphologic forms: oval to round blastospores or yeast cells (3-6 mm in diameter); double-walled chlamydospores (7-17 mm in diameter), which are usually at the terminal end of a pseudohypha; and pseudomycelium, which is a mass of pseudohyphae and represents the tissue phase of Candida. Pseudohyphae are filamentous processes that elongate from the yeast cell without the cytoplasmic connection of a true hypha. Candida grows aerobically on routine laboratory media but can require several days of incubation.


C. albicans accounts for most human infections, but C. parapsilosis, C. tropicalis, C. krusei, C. lusitaniae, C. glabrata, and several other species are commonly isolated from hospitalized children. C. albicans forms a germ tube when suspended in rabbit or human serum and incubated for 1-2 hr; a rapid germ tube test should therefore be performed before further identification tests are conducted. Thereafter, differentiation and susceptibility testing are important owing to increasing frequency of fluconazole resistance. The other clinically important Candida species can be identified within 48 hr on the basis of biochemical test results.


Treatment of invasive Candida infections is complicated by the emergence of non-albicans strains. Amphotericin B deoxycholate is inactive against approximately 20% of strains of C. lusitaniae. Fluconazole is useful for many Candida infections but is inactive against all strains of C. krusei and 5-25% of strains of C. glabrata. Susceptibility testing of these clinical isolates is recommended.



226.1 Neonatal Infections




Candida is a common cause of oral mucous membrane infections (thrush) and perineal skin infections (Candida diaper dermatitis) in newborn infants (Chapter 658). Rare presentations include congenital cutaneous candidiasis, caused by an ascending infection into the uterus during gestation, and invasive fungal dermatitis, a postnatal infection skin infection resulting in positive blood cultures. Invasive candidiasis is a common infectious complication in the neonatal intensive care unit (NICU) because of improved survival of the extremely preterm infants.







Treatment


In the absence of systemic manifestations, topical antifungal therapy is the treatment of choice for congenital cutaneous candidiasis in full-term infants. Congenital cutaneous candidiasis in preterm infants can progress to systemic disease, and therefore systemic therapy is warranted.


Every attempt should be made to remove or replace central venous catheters once the diagnosis of candidemia is confirmed. Delayed removal has been consistently associated with increased mortality and morbidity including poor neurodevelopmental outcomes. No well-powered randomized, controlled trials exist to guide length and type of therapy.


Systemic antifungal therapy should be administered for 21 days from the last positive Candida culture. Amphotericin B deoxycholate has been the mainstay of therapy for systemic candidiasis and is active against both yeast and mycelial forms. Nephrotoxicity, hypokalemia, and hypomagnesemia are common, but amphotericin B deoxycholate is better tolerated in neonates than in adult patients. C. lusitaniae, an uncommon pathogen in neonates, is resistant to amphotericin B deoxycholate. Fluconazole is very useful for treatment of invasive neonatal Candida infections, especially urinary tract infections. Fluconazole is inactive against all strains of C. krusei and some isolates of C. glabrata.

Stay updated, free articles. Join our Telegram channel

Jun 18, 2016 | Posted by in PEDIATRICS | Comments Off on Candida

Full access? Get Clinical Tree

Get Clinical Tree app for offline access